» Articles » PMID: 38067510

Synthesis of Novel Arginine Building Blocks with Increased Lipophilicity Compatible with Solid-Phase Peptide Synthesis

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2023 Dec 9
PMID 38067510
Authors
Affiliations
Soon will be listed here.
Abstract

Arginine, due to the guanidine moiety, increases peptides' hydrophilicity and enables interactions with charged molecules, but at the same time, its presence in a peptide chain might reduce its permeability through biological membranes. This might be resolved by temporary coverage of the peptide charge by lipophilic, enzyme-sensitive alkoxycarbonyl groups. Unfortunately, such a modification of a guanidine moiety has not been reported to date and turned out to be challenging. Here, we present a new, optimized strategy to obtain arginine building blocks with increased lipophilicity that were successfully utilized in the solid-phase peptide synthesis of novel arginine vasopressin prodrugs.

Citing Articles

PIEZO2 Proton Affinity and Availability May Also Regulate Mechanical Pain Sensitivity, Drive Central Sensitization and Neurodegeneration.

Sonkodi B Int J Mol Sci. 2025; 26(3).

PMID: 39941012 PMC: 11818069. DOI: 10.3390/ijms26031246.

References
1.
Schug K, Lindner W . Noncovalent binding between guanidinium and anionic groups: focus on biological- and synthetic-based arginine/guanidinium interactions with phosph[on]ate and sulf[on]ate residues. Chem Rev. 2005; 105(1):67-114. DOI: 10.1021/cr040603j. View

2.
Santana A, Francisco C, Suarez E, Gonzalez C . Synthesis of guanidines from azides: a general and straightforward methodology in carbohydrate chemistry. J Org Chem. 2010; 75(15):5371-4. DOI: 10.1021/jo100876r. View

3.
Bionda N, Cudic P . Solid-phase guanidinylation of peptidyl amines compatible with standard Fmoc-chemistry: formation of monosubstituted guanidines. Methods Mol Biol. 2013; 1081:151-65. DOI: 10.1007/978-1-62703-652-8_10. View

4.
Rader A, Weinmuller M, Reichart F, Schumacher-Klinger A, Merzbach S, Gilon C . Orally Active Peptides: Is There a Magic Bullet?. Angew Chem Int Ed Engl. 2018; 57(44):14414-14438. DOI: 10.1002/anie.201807298. View

5.
Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W . The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2007; 36(2):386-99. DOI: 10.1124/dmd.107.019083. View